Phase 1 clinical trials are the highest-paying paid research studies available to healthy volunteers, but the real numbers are more nuanced than the $2,000 to $10,000 range you see quoted online. According to a peer-reviewed study by Fisher et al. published in the journal *Clinical Trials* in 2021, the median Phase 1 compensation is actually $3,070, with a full range spanning $150 to $13,000. The majority of trials — 65.1 percent — offered less than $4,000 in total compensation, and fewer than 2 percent paid above $10,000.
So while the $2,000 to $10,000 claim is broadly accurate, it skews toward the higher end of what most participants will realistically earn. That said, Phase 1 studies still pay significantly more than almost any other type of paid research opportunity, including focus groups, online surveys, and market research panels. A single inpatient study lasting a few weeks can net you what months of survey panels would. The catch is that these payouts come with real trade-offs — you may need to spend consecutive days and nights in a research clinic, undergo blood draws and monitoring around the clock, and accept that you are testing a compound that has never been given to humans before. This article breaks down exactly how much Phase 1 trials pay, what drives those numbers up or down, how much serial volunteers actually earn per year, and what you should know before signing up.
Table of Contents
- How Much Do Phase 1 Clinical Trials Actually Pay Healthy Volunteers?
- What Determines Whether a Study Pays $500 or $10,000?
- How Much Do Serial Clinical Trial Volunteers Earn Per Year?
- How Phase 1 Trial Pay Compares to Other Paid Research Opportunities
- The Ethics of Phase 1 Pay and What IRBs Watch For
- Where to Find the Highest-Paying Phase 1 Trials
- The Future of Phase 1 Compensation and Volunteer Protections
- Conclusion
- Frequently Asked Questions
How Much Do Phase 1 Clinical Trials Actually Pay Healthy Volunteers?
The short answer is that most Phase 1 clinical trials pay between $1,500 and $5,000, with the median sitting at $3,070. That figure comes from the Fisher et al. analysis of compensation across hundreds of Phase 1 studies in the United States. The lowest-paying study in their dataset was a $150 vaccine trial that required no clinic confinement at all — basically a shot and a few follow-up visits. The highest was a $13,000 cancer study that required participants to live in a research clinic for 34 consecutive days and nights.
When you break the compensation down by time spent, most studies work out to roughly $10 to $20 per hour of participant time, which is decent but not the windfall some recruitment ads imply. The wide range exists because Phase 1 trials vary enormously in what they ask of you. A simple outpatient pharmacokinetic study where you take a single dose and come back for a few blood draws might pay $500 to $1,500. An inpatient study requiring a week-long stay with daily monitoring, restricted diet, and multiple dosing periods will typically land in the $2,000 to $5,000 range. The studies that cross into five figures almost always involve extended confinement periods of three weeks or more, first-in-human compounds with unknown risk profiles, or therapeutic areas like oncology where the monitoring is especially intensive. If someone quotes you $8,000 or $10,000 for a Phase 1 trial, expect to essentially move into the clinic for the better part of a month.
What Determines Whether a Study Pays $500 or $10,000?
Four main factors drive Phase 1 compensation: the trial phase and design, the duration and number of visits, whether the study is inpatient or outpatient, and the risk level involved. Inpatient studies requiring overnight stays pay significantly more than outpatient studies because they demand far more of your time and autonomy. You are not just showing up for an appointment — you are living in a controlled environment, eating what the study provides, and following a rigid schedule. That level of inconvenience is reflected in the payment. The therapeutic area also matters more than most people realize.
Studies involving cardiovascular drugs, neurology compounds, endocrine treatments, gastrointestinal medications, and blood disorder therapies tend to pay the most. First-in-human studies — where a drug is being tested in people for the very first time — command a premium because of the unknown risk profile and the intensive monitoring required. These studies typically involve more frequent blood draws, longer observation periods, and closer medical supervision, all of which translate to higher compensation. However, if you are expecting to walk into any Phase 1 trial and pocket $5,000-plus, you will likely be disappointed. The majority of available studies cluster in the $1,500 to $4,000 range, and the high-paying outliers fill up fast because experienced volunteers know which clinics and compounds pay the most. Geographic location plays a role too — studies in major metro areas with multiple competing research sites tend to offer higher compensation than those in smaller markets.
How Much Do Serial Clinical Trial Volunteers Earn Per Year?
There is a community of people who participate in clinical trials as a regular income source, sometimes called “professional guinea pigs” or serial volunteers. The research paints a more modest picture of their earnings than you might expect. According to data on healthy volunteer participation patterns, active trial seekers tend to screen for about three studies per year, actually participate in one to two of them, and earn roughly $4,000 annually from clinical trials.
That gap between screening and participation exists because not everyone who applies qualifies — eligibility criteria can be strict, and washout periods between studies create scheduling conflicts. Earning more than $10,000 to $20,000 in a single year from clinical trials alone is unusual, and researchers describe earning above $20,000 annually as “exceedingly rare.” The limiting factors are washout periods — most clinics require 30 to 90 days between studies — health screening requirements that can disqualify you if your labs shift, and the simple fact that high-paying inpatient studies take weeks to complete, leaving less calendar time for additional trials. For context, a volunteer who lands two solid inpatient studies at $3,000 each and one shorter outpatient study at $1,000 has a realistic annual haul of around $7,000. Not nothing, but not a full-time income either.
How Phase 1 Trial Pay Compares to Other Paid Research Opportunities
Phase 1 trials sit at the top of the paid research compensation hierarchy, but they also demand the most. A typical two-hour focus group pays $100 to $250. An online survey panel might pay $1 to $5 per survey. Even multi-day market research ethnography studies rarely exceed $500 to $1,000. By comparison, a single Phase 1 inpatient study can pay $2,000 to $5,000 for one to two weeks of participation. On a per-study basis, nothing else in the paid research world comes close.
The trade-off is time, physical commitment, and risk. Focus groups and surveys require minimal effort and carry zero physical risk. You show up, share your opinion, and leave. Phase 1 trials involve medical screening, potential side effects, dietary restrictions, and in many cases, days or weeks confined to a research facility. The hourly rate, when calculated honestly at $10 to $20 per hour, is actually comparable to what you might earn doing focus groups — the difference is that trials consolidate that earning into a single lump sum over a concentrated period. If you value schedule flexibility and low commitment, stacking focus groups and survey panels may be preferable. If you are comfortable with the medical aspects and have blocks of free time, Phase 1 trials offer a more substantial single payout.
The Ethics of Phase 1 Pay and What IRBs Watch For
Every clinical trial’s compensation structure is reviewed by an Institutional Review Board before the study can recruit participants. IRBs are specifically tasked with ensuring that payment constitutes fair compensation for time and inconvenience without crossing into “undue inducement” — meaning the money should not be so high that it pressures people into accepting risks they would otherwise avoid. This is why Phase 1 compensation does not simply scale linearly with risk. A study with a genuinely dangerous compound will not necessarily pay $50,000 to attract volunteers; instead, the IRB may require additional safety monitoring, slower dose escalation, or other protective measures. A 2025 investigation by STAT News highlighted the ongoing debate about whether healthy research volunteers are paid fairly, particularly in high-risk human challenge studies where participants are deliberately exposed to pathogens. The tension is real: pay too little and you are exploiting participants who bear genuine physical risk for the advancement of medicine.
Pay too much and you risk attracting people who cannot afford to say no, regardless of how they feel about the danger involved. For participants, the practical takeaway is that compensation is designed to be reasonable, not extravagant. If a study is advertising dramatically higher pay than comparable trials at other clinics, ask why — it may involve higher risk, longer confinement, or more invasive procedures than you anticipated. One limitation worth noting: compensation structures vary internationally. Studies in the United States generally pay more than those in Canada, Europe, or other markets. If you are comparing pay across different countries, the figures cited in this article apply specifically to the U.S. research landscape.
Where to Find the Highest-Paying Phase 1 Trials
The highest-paying Phase 1 studies are typically run by dedicated Phase 1 clinical pharmacology units — standalone research clinics that specialize in early-phase drug testing. Names like Celerion, PPD, Worldwide Clinical Trials, and Parexel operate large inpatient facilities across the U.S. and regularly post studies in the $3,000 to $8,000 range. ClinicalTrials.gov is the official federal database where all registered trials are listed, though compensation details are not always included in listings.
Most experienced volunteers monitor the websites of several research clinics directly and sign up for their volunteer databases to receive study notifications as soon as new trials open for recruitment. Timing matters. Studies recruiting over holidays, during school semesters, or requiring uncommon demographics — such as healthy volunteers over age 60 or people with specific genetic markers — sometimes pay a premium because they are harder to fill. Being flexible with your schedule and responsive when a clinic contacts you about a new study gives you a meaningful advantage over volunteers who can only participate during summers or breaks.
The Future of Phase 1 Compensation and Volunteer Protections
The conversation around clinical trial compensation is shifting. Advocacy groups and bioethicists are increasingly pushing for standardized payment frameworks that account for both time and risk in a transparent way, rather than leaving it to each sponsor and IRB to negotiate independently. Some researchers have proposed per-hour minimums benchmarked to local wages, while others argue for additional compensation tiers based on study invasiveness and confinement requirements.
Technology is also changing the landscape. Decentralized trial models that allow some monitoring to happen remotely through wearable devices and telemedicine visits could reduce the burden on participants and potentially reshape how compensation is structured. For now, though, the fundamentals remain the same: Phase 1 trials pay healthy volunteers more than any other type of paid research study, the median sits around $3,000, and the top end requires significant personal sacrifice in time and freedom. Going in with realistic expectations — and a clear understanding of what the study involves — is the best way to decide whether the compensation is worth it for you.
Conclusion
Phase 1 clinical trials remain the gold standard for paid research compensation, offering healthy volunteers payouts that dwarf what focus groups, surveys, and market research studies can match. But the reality is more measured than the $2,000 to $10,000 range suggests at first glance. With a median payment of $3,070 and nearly two-thirds of studies paying under $4,000, most participants will earn in the low thousands per study.
The five-figure payouts exist but are rare, accounting for less than 2 percent of studies, and they come with weeks of inpatient confinement. If you are considering Phase 1 trials as a way to earn extra income, approach it with clear eyes. Research multiple clinics, compare what different studies require versus what they pay, and factor in the screening process, washout periods, and time commitment when calculating your real hourly rate. Clinical trials contribute to medical progress and compensate you for that contribution — but they are neither a get-rich-quick scheme nor something to enter without reading every page of that informed consent document.
Frequently Asked Questions
Do you have to be completely healthy to join a Phase 1 trial?
Generally yes. Phase 1 trials for healthy volunteers require you to pass medical screening including blood work, vital signs, and sometimes an EKG. Most clinics exclude people with chronic conditions, those taking prescription medications, and anyone with a BMI outside their target range. Some studies specifically recruit people with certain conditions, but those are typically Phase 2 or Phase 3 trials.
How long do you have to wait between Phase 1 studies?
Most research clinics enforce a washout period of 30 to 90 days between studies, depending on the drug involved. This is both for your safety and for data integrity — residual compounds from a previous study could interfere with the next one. This waiting period is a key reason why annual earnings from serial trial participation top out around $4,000 for most volunteers.
Can you leave a Phase 1 trial once it starts?
Yes. Participation in any clinical trial is voluntary, and you have the legal right to withdraw at any time for any reason. However, most studies prorate compensation based on how much of the study you complete, so leaving early means receiving only partial payment. Read the informed consent document carefully to understand the payment schedule before you check in.
Are Phase 1 trials dangerous?
Phase 1 trials carry more uncertainty than later-phase studies because the drug may have never been tested in humans before. Serious adverse events are rare but not impossible. The 2006 TGN1412 incident in London, where six volunteers experienced severe organ failure during a first-in-human trial, remains a cautionary benchmark. Modern protocols include staggered dosing and extensive safety monitoring to minimize risk, but it is never zero.
Do you have to pay taxes on clinical trial compensation?
In the United States, clinical trial compensation is considered taxable income. If you earn $600 or more from a single research site in a calendar year, the site is required to issue you a 1099 form. Even if you earn less than $600, you are technically required to report the income. Keep records of all payments received.
Is clinical trial compensation paid all at once or in installments?
It depends on the study. Short outpatient studies may pay a lump sum at your final visit. Longer inpatient studies often pay in installments — for example, a portion at check-in, a portion at discharge, and a final payment after your last follow-up visit. This structure is partly designed to encourage completion of all study visits, including follow-ups that happen weeks after the main confinement period.
